Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 13, 2021; 96 (15 Supplement) Saturday, April 17

Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 3 Copies of SMN2 (4163)

Kevin Strauss, Francesco Muntoni, Michelle Farrar, Kayoko Saito, Jerry Mendell, Laurent Servais, Hugh McMillan, Kathryn Swoboda, Jennifer Kwon, Craig Zaidman, Claudia Chiriboga, Susan Iannaccone, Jena Krueger, Julie Parsons, Perry Shieh, Sarah Kavanagh, Deepa Chand, Sitra Tauscher-Wisniewski, Thomas Macek
First published April 13, 2021,
Kevin Strauss
1Clinic for Special Children
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Muntoni
2The Dubowitz Neuromuscular Centre, University College London, Great Ormond Street Institute of Child Health & Great Ormond Street Hospital
3National Institute of Health Research, Great Ormond Street Hospital Biomedical Research Centre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Farrar
4Department of Neurology, Sydney Children’s Hospital Network
5UNSW Sydney
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kayoko Saito
6Institute of Medical Genetics, Tokyo Women’s Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry Mendell
7Center for Gene Therapy, Nationwide Children’s Hospital
8Department of Pediatrics and Department of Neurology, Ohio State University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Servais
9Department of Pediatrics, MDUK Oxford Neuromuscular Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugh McMillan
10Department of Pediatrics, Children’s Hospital of Eastern Ontario
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn Swoboda
11Department of Neurology, Massachusetts General Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Kwon
12Department of Neurology, University of Wisconsin School of Medicine and Public Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Zaidman
13Washington University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Chiriboga
14Division of Pediatric Neurology, Columbia University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Iannaccone
15Department of Pediatrics, University of Texas Southwestern Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jena Krueger
16Department of Neurology, Helen DeVos Children’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Parsons
17Department of Pediatrics, University of Colorado School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Perry Shieh
18Department of Neurology, David Geffen School of Medicine at UCLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Kavanagh
19Novartis Gene Therapies, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepa Chand
13Washington University School of Medicine
19Novartis Gene Therapies, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sitra Tauscher-Wisniewski
19Novartis Gene Therapies, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Macek
19Novartis Gene Therapies, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 3 Copies of SMN2 (4163)
Kevin Strauss, Francesco Muntoni, Michelle Farrar, Kayoko Saito, Jerry Mendell, Laurent Servais, Hugh McMillan, Kathryn Swoboda, Jennifer Kwon, Craig Zaidman, Claudia Chiriboga, Susan Iannaccone, Jena Krueger, Julie Parsons, Perry Shieh, Sarah Kavanagh, Deepa Chand, Sitra Tauscher-Wisniewski, Thomas Macek
Neurology Apr 2021, 96 (15 Supplement) 4163;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Evaluate the safety/efficacy of onasemnogene abeparvovec (formerly AVXS-101) in presymptomatic SMA patients with 3 copies of the survival motor neuron 2 gene (SMN2).

Background: SMA causes loss of motor/respiratory function due to SMN1 deletion/mutation. Copies of SMN2 modify disease severity. A range of phenotypes may occur with 3SMN2 with approximately 85% developing symptoms in infancy and not being able to walk independently without intervention.

Design/Methods: SPR1NT (NCT03505099) is an ongoing multicenter, open-label, Phase III study. Asymptomatic patients expected to develop SMA (Cohort 2: 3SMN2, ≤6 weeks) received a one-time intravenous infusion and are assessed through 24 months. Primary outcome: standing unassisted for ≥3 seconds. Secondary outcome: independent walking. Safety outcomes: incidence of adverse events (AEs)/serious AEs.

Results: As of 11 June 2020, 15 patients in Cohort 2 were enrolled (enrollment complete). Median age (range) at last visit (months): 15.2 (3.3–21.1); median follow-up time (range) at last visit (months): 14.5 (2.0–19.9). All patients are alive and none used ventilatory or feeding tube support at any time. Eight of 15 Cohort 2 patients had achieved the primary efficacy endpoint of stands alone within the normal developmental window (16.9 months, De Onis 2006). The remaining 7 patients were all younger than 16.9 months of age. Six patients also walked alone within the normal developmental window (17.6 months, De Onis 2006); remaining patients were younger than 17.6 months of age. Within the whole SPR1NT study population 30/30 patients (14 2SMN2, 15 3SMN2, and 1 4SMN2 patient included only in the safety population) experienced ≥1 AE; 17/30 experienced treatment-related AEs. 7/13 experienced a serious AE, but all resolved and were considered unrelated to treatment.

Conclusions: Patients in this cohort treated with onasemnogene abeparvovec have achieved gross motor milestones similar to non-SMA, typically developing peers, demonstrating a significant therapeutic benefit.

Disclosure: Kevin Strauss has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AveXis. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sarepta. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Avexis. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Muntoni has received research support from European Commission. The institution of Dr. Muntoni has received research support from Medical Research Council. The institution of Dr. Muntoni has received research support from Biogen. The institution of Dr. Muntoni has received research support from Muscular Dystrophy UK. The institution of Dr. Muntoni has received research support from MDA USA. The institution of Dr. Muntoni has received research support from Sarepta. The institution of Dr. Muntoni has received research support from Association Francoise Myopathies. Dr. Muntoni has received personal compensation in the range of $0-$499 for serving as a Clinical expert with UK NICE Committee. Michelle Farrar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Michelle Farrar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Michelle Farrar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Michelle Farrar has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Michelle Farrar has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Kyoko Saito has nothing to disclose. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Vertex. Dr. Mendell has received research support from Sarepta. The institution of Dr. McMillan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AveXis. Dr. McMillan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AveXis. The institution of Dr. McMillan has received research support from Roche. Dr. Swoboda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Swoboda has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Swoboda has received research support from Biogen. Dr. Kwon has nothing to disclose. Dr. Zaidman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Zaidman has received research support from Biogen. Dr. Chiriboga has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentec. Dr. Chiriboga has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Chiriboga has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avexis. Dr. Chiriboga has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Chiriboga has received research support from Roche. The institution of Dr. Chiriboga has received research support from Avexis. The institution of Dr. Chiriboga has received research support from Biogen. The institution of Dr. Chiriboga has received research support from NIH. Dr. Chiriboga has received publishing royalties from a publication relating to health care. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AveXis. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AveXis. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catabasis. The institution of Dr. Iannaccone has received research support from AveXis. The institution of Dr. Iannaccone has received research support from Biogen. The institution of Dr. Iannaccone has received research support from Sarepta. The institution of Dr. Iannaccone has received research support from PTC Therapeutics. The institution of Dr. Iannaccone has received research support from FibroGen. The institution of Dr. Iannaccone has received research support from ReveraGen. The institution of Dr. Iannaccone has received research support from MDA. The institution of Dr. Iannaccone has received research support from PPMD. The institution of Dr. Iannaccone has received research support from NIH. Dr. Iannaccone has received personal compensation in the range of $0-$499 for serving as a grant reviewer with NIH. Dr. Krueger has nothing to disclose. Dr. Parsons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AveXis. Dr. Parsons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Parsons has received research support from AveXis. The institution of Dr. Parsons has received research support from Biogen. The institution of Dr. Parsons has received research support from Scholar Rock. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Shieh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for PTC. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Grifols. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Shieh has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Shieh has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Avexis. Sarah Kavanagh has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for UCB Pharma. Sarah Kavanagh has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Colorado Prevention Center. Sarah Kavanagh has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for PureTech Health. Sarah Kavanagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Worldwide Clinical Trails. Deepa Chand has received personal compensation for serving as an employee of Novartis Gene Therapies. Deepa Chand has received stock or an ownership interest from Novartis. Deepa Chand has received publishing royalties from a publication relating to health care. Sitra Tauscher-Wisniewski has received personal compensation for serving as an employee of Novartis Gene Therapies. Thomas Macek has received personal compensation for serving as an employee of Novartis . Thomas Macek has received stock or an ownership interest from Novartis .

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise